COVID-19 vaccine update: new formulation now available
As of 15 November 2025, the Pfizer (COMIRNATY) LP.8.1 formulation is the most recent COVID-19 vaccine available in Australia. This update applies across all age groups:
6 months – <5 years: 3 mcg/0.3 mL (multi-dose vial, requires dilution)
5 – <12 years: 10 mcg/0.3 mL (single-dose vial)
12 years and older: 30 mcg/0.3 mL (single-dose prefilled syringe)
Please replace previous posters and display the updated COVID-19 vaccines in Australia – A3 poster in your clinical areas.
➡️ Download the poster here: COVID-19 vaccines in Australia – A3 poster (PDF)
Key clinical guidance
For the latest recommendations on primary courses and additional doses, refer to the Australian Immunisation Handbook:
Adults aged 18 years and over: Recommended a single primary dose.
Children and adolescents under 18 years: Not routinely recommended a primary dose.
People with severe immunocompromise (6 months and older): Recommended 2 primary doses, with eligibility for a third dose based on individual risk-benefit assessment.
Infants, children and adolescents (6 months to <18 years) with conditions other than severe immunocompromise that may increase the risk of severe COVID-19: Eligible for primary dose(s) based on risk-benefit assessment.
Storage and handling
If vaccines are stored or handled outside the conditions listed on the poster, complete a Cold Chain Breach (CCB) reporting form and email it to the Vaccine Operations Centre: COVID19VaccineOperationsCentre@health.gov.au
Reporting requirements
Under the Australian Immunisation Register Act 2015, all vaccinations administered in Australia must be reported to the AIR.
For more details, visit: Advice for COVID-19 vaccine providers and administrators.
